FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer
Condition The purpose of the FACE intervention is to facilitate conversations about EOL care
between adolescents and their legal guardians or surrogates in order to increase congruence
in treatment preferences, to decrease decisional conflict, while supporting plans and
actions, psychological adjustment and quality of life. This intervention will consist of
three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Each
session will be followed by a 15 minute assessment, using process measures to assess
participants' ratings of the quality of the communication with the facilitator and
satisfaction (negative and positive emotions in response to session) on a Likert scale. A
research assistant, not the facilitator, will conduct the immediate post evaluation
sessions. A Standard of Care comparison condition will also be assessed and measures
administered at the same time intervals: at baseline, one week intervals for three weeks for
process measures and Statement of Treatment Preferences, and at 3 month-post intervention
follow-up.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Statement of Treatment Preferences
Statement of Treatment Preferences expresses values and goals related to future decision making regarding frequently occurring scenarios common to individuals dying of cancer). This instrument will be used to document specific treatment preferences of patients and the surrogate's understanding of what the patient would want. Patients and surrogates choose one of three options, "to continue all treatment and keep fighting," "to stop all treatment to prolong my life," and "don't know." It can also be used to monitor changes in patient's preferences over time. This tool has been used in adults and in adolescents in the FACE study conducted by the PI.
Week 3
No
Maureen E Lyon, PhD
Principal Investigator
Children's Research Institute, Children's National Medical Center
United States: Institutional Review Board
PEP-10-171-01-PCSM
NCT01670461
January 2009
June 2013
Name | Location |
---|---|
Children's National Medical Center | Washington, District of Columbia 20010-2970 |